AbCellera IPO Presentation Deck

DISCLAIMERS This presentation has been prepared by AbCellera Biologics Inc. ("we","pur" or the "Company"). The information set forth berein does not purport to be complete or to contain all of the information you may desire. Statements contained herein are made as of the date of this presentation unless stated otherwise, and neither the presentation, nor any sale of securities, shall under any circumstances create an implication that the information contained herein is correct as of any time after such date or that information will be updated or revised to reflect information that subsequently becomes available or changes occurring after the date hereof. This presentation includes forward-looking statements regarding our business, strategy, technology, ability to discover and deliver antibodies to our partners, strategic plans, acquisitions, partnerships, including the development and commercialization of any antibodies that we deliver to our partners, expected revenues that we may receive from our partnerships, market sizing and expectations, results from operations and other matters. Actual results could differ materially from those contained in any forward-looking statements as a result of various factors, including without imitation: the quality of our antibody discovery platform and technological capabilities and their acceptance by now and existing partners in our market, our ability to maintain or expand our current partnerships or enter into new partnerships: our dependence in recent periods on a limited number of partners for our revenue: the inherent uncertainty associated with biopharmaceutical drug development and the possibility that our partners do not further develop the drug candidates that we discover and deliver, or that our partners do not secure marketing approval or experience commercial success with respect to such candidates our ability to manage our current and future growth; our ability to capitalize on the investments that we have made and intend to make to our technology: our partners ability to achieve projected discovery and development milestones and other anticipated key events in the expected timelines or at all our ability to compete in the life sciences and biotech platform technology market our ability to protect our intellectual property and the other risk factors contained in the preliminary prospectus to which this offering relates. We undertake no obligation to update forward-looking statements as a result of new information of otherwise. AbCellera This presentation also contains estimates and other statistical data made by independent parties and by us relating to market size and growth and other data about our industry. This data involves a number of assumptions and imitations and you are cautioned not to give undue weight to such estimates. In addition, projections, assumptions, and estimates of our future performance and the future performance of the markets in which we operate are necessarily subject to a high degree of uncertainty and risk We have filed a registration statement on Form 5-1 (including a preliminary prospectus) with the Securities and Exchange Commission (the "SEC") for the offering to which this communication relates. The regstration statement has not yet become effective. Our common shares may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. Before you invest, you should read the preliminary prospectus and the other documents we file with the SEC for more complete information about us and this offering, You can obtain these documents for free by visiting EDGAR on the SEC website at www.sec.gov. Alternatively, copies of the preliminary prospectus may be obtained from: Credit Suisse Securities (USA) LLC, Attention: Prospectus Department, 6933 Louis Stephens Drive, Monivile, North Carolina 27560, United States. by telephone at (800) 221-1037, or by email at una [email protected]: Stifel, Nicolaus & Company, Incorporated. Attention: Prospectus Department. One Montgomery Street, Suite 3700. San Francisco, CA 94104 by telephone at (415) 364 2720, or by email at [email protected] Berenberg Capital Markets LLC. Attention: Investment Banking, 1251 Avenue of the American, 53rd Floor, New York, NY 10020, by telephone at (646) 949-9000, or by email at [email protected] SVB Leerink LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, by telephone at (800) 808-7525. ext. 6132, or by email at [email protected] or BMD Capital Markets Corp., 3 Times Square, New York, NY 10036, Attention: Equity Syndicate Department, by telephone at (800)414 3627, or by email at [email protected] This presentation shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

View entire presentation